GlaxoSmithKline has begun shipping doses of its quadrivalent influenza vaccine, Fluarix, to US healthcare providers in preparation for the 2014-2015 flu season.
GlaxoSmithKline also received 2014-2015 license approvals by the FDA for its other three influenza vaccines — two trivalent vaccines (Fluarix and Flulaval) and another quadrivalent vaccine (Flulaval). The pharmaceutical company will begin shipping the Flulaval trivalent and quadrivalent vaccines in early August, pending additional FDA lot releases. It expects to supply between 28 million and 33 million doses of all four vaccines for the approaching influenza season.
Each of the vaccines are indicated for use in individuals aged 3 years and older. The CDC recommends that those aged 6 months or older should be vaccinated annually. However, the agency does not recommend a four-strain dose over a three-strain dose, instead leaving the choice up to providers and their patients.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management